<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107704">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02068963</url>
  </required_header>
  <id_info>
    <org_study_id>P10433-HCVQPS-01</org_study_id>
    <nct_id>NCT02068963</nct_id>
  </id_info>
  <brief_title>Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing</brief_title>
  <official_title>Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hologic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hologic, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional clinical study will be conducted to prospectively collect serial
      plasma and serum samples from treatment naïve subjects with chronic HCV infection who are
      initiating sofosbuvir-based therapy. These samples will be used to estimate clinical utility
      endpoints for the Aptima HCV Quant Dx assay which is used an aid in the management of
      HCV-infected patients undergoing HCV antiviral therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Sustained viral response based on lower limit of quantitation</measure>
    <time_frame>12 weeks post therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sustained viral response (SVR) is defined as viral load level being below the investigational assay's lower limit of quantitation.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Study Population</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment naïve men and women ≥18 years of age with chronic HCV infection initiating
        sofosbuvir-based treatment will be enrolled from medical facilities that may include
        private and academic family practice, infectious disease, hepatology, gastroenterology,
        and medical group clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is chronically infected with HCV genotypes 1, 2, 3, 4, 5, and/or 6 as
             documented in the subject's medical records and is naïve to HCV treatment (treatment
             naïve).

          -  Chronic HCV (with or without HIV [human immunodeficiency virus] co-infection) will be
             documented with historical record of:

          -  A positive HCV RNA test result (result generated at least 6 months before the
             baseline visit)

          -  A HCV genotype test result (result generated at least 6 months before the baseline
             visit)

          -  A liver biopsy report demonstrating chronic HCV

             ---The subject is initiating antiviral therapy with a sofosbuvir regimen as indicated
             below:

          -  Sofosbuvir plus peginterferon and ribavirin for 12 weeks (peginterferon eligible
             genotype 1, 4, 5, or 6)

          -  Sofosbuvir plus ribavirin for 12 weeks (genotype 2)

          -  Sofosbuvir plus ribavirin for 24 weeks (peginterferon ineligible or unwilling
             genotype 1 or genotype 3)

          -  The subject is at least 18 years of age at the time of enrollment

          -  Adequate medical records are available for collection of protocol-defined
             demographics, baseline patient characteristics, medical history, virology and
             specific laboratory results, and other information to verify enrollment criteria

          -  The subject and/or legally authorized representative is willing and able to provide
             consent prior to providing a specimen(s)

        Exclusion Criteria:

          -  Subjects with history or evidence of decompensated liver disease

          -  Subjects with severe renal impairment or end stage renal disease

          -  Subjects who are not naïve to HCV therapy with prior exposure to an approved or
             experimental HCV antiviral therapy

          -  Subject has characteristics that are contraindicated in the FDA approved label for
             sofosbuvir (eg, subjects with contraindications applicable to peginterferon and/or
             ribavirin, pregnant woman or men whose female partners are pregnant; Sovaldi Package
             Insert 2013)

          -  Subject is receiving treatment pre- or post-transplant

          -  Subject is unsuitable for study participation based on the Investigator's decision
             (eg, unlikely to comply with study visit schedule, significant medical complication)

          -  Participating in another investigational study that the Investigator believes might
             interfere with the subject's participation in this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer L Reid, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hologic, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Franco Felizarta, MD</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Felizarta, MD</last_name>
      <phone>661-324-3128</phone>
      <email>ffelizarta@felizartamd.com</email>
    </contact>
    <investigator>
      <last_name>Franco Felizarta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Gastroenterology, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcelo Kugelmas, MD</last_name>
      <phone>303-406-4139</phone>
      <email>Kugelmas@gutfeelings.com</email>
    </contact>
    <investigator>
      <last_name>Marcelo Kugelmas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pointe West Infectious Diseases</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eliot Godofsky, MD</last_name>
      <phone>941-746-2711</phone>
      <email>Egodofsky@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eliot Godofsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Gitlin, MD</last_name>
      <phone>404-881-1094</phone>
      <email>nmgitlin@aol.com</email>
    </contact>
    <investigator>
      <last_name>Norman Gitlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aasim Sheikh, MD</last_name>
      <phone>678-819-4237</phone>
      <email>amsheikh@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Aasim Sheikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indianapolis Gastroenterology Research Facility</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Pound, MD</last_name>
      <phone>317-865-2959</phone>
      <email>dpound@indygastro.com</email>
    </contact>
    <investigator>
      <last_name>David Pound, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Y. Kwo, MD</last_name>
      <phone>317-274-3090</phone>
      <email>pkwo@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Y. Kwo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Gastroenterology</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Freilich, MD</last_name>
      <phone>816-509-4999</phone>
      <email>Brad@kcgastro.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Freilich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asheville Gastroenterology Associates, PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William R. Harlan, III, MD</last_name>
      <phone>828-254-0881</phone>
      <email>research@ashevillegastro.com</email>
    </contact>
    <investigator>
      <last_name>William R. Harlan, III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Tillmann, MD</last_name>
      <phone>919-668-4620</phone>
      <email>hans.tillmann@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Hans Tillmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Options Health Research, LLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harvey A. Tatum, MD</last_name>
      <phone>918-513-3490</phone>
      <email>harvey.tatum@okgastro.com</email>
    </contact>
    <investigator>
      <last_name>Harvey A. Tatum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Block Medical Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15238</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geoffrey Block, MD</last_name>
      <phone>412-826-9380</phone>
      <phone_ext>205</phone_ext>
      <email>gdblock@blockmed.com</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert W Herring, Jr, MD</last_name>
      <phone>615-835-4709</phone>
      <email>rherring@qualitymedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Robert W Herring, Jr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Associates of Texas, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Ankoma-Sey, MD</last_name>
      <phone>713-799-2667</phone>
      <email>akobot@aol.com</email>
    </contact>
    <investigator>
      <last_name>Victor Ankoma-Sey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Specialists of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph S. Galati, MD</last_name>
      <phone>713-256-6227</phone>
      <email>drgalati@texasliver.com</email>
    </contact>
    <investigator>
      <last_name>Joseph S. Galati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fred Poordad, MD</last_name>
      <phone>210-253-3426</phone>
      <email>poordad@txliver.com</email>
    </contact>
    <investigator>
      <last_name>Fred Poordad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Associates of Central Virginia</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Brennan, MD</last_name>
      <phone>434-947-3944</phone>
      <email>robert.brennan@macvmd.com</email>
    </contact>
    <investigator>
      <last_name>Robert Brennan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ryan, MD</last_name>
      <phone>757-466-0165</phone>
      <email>mjrresearch@dlds.org</email>
    </contact>
    <investigator>
      <last_name>Michael Ryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Instititute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell L. Shiffman, MD</last_name>
      <phone>804-301-7058</phone>
      <email>mitchell_shiffman@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell L. Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Landis, MD PhD</last_name>
      <phone>206-744-3402</phone>
      <email>Claudia@medicine.Washington.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Landis, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
